Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer’s disease

Greig, NigelH; Unnisa, Aziz; Kamal, MohammadAmjad

doi:10.4103/1673-5374.369096

Cited by 11 publications

(5 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Organoids have not only been developed for AD but have also been cultured for other neurological diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and Huntington’s disease. Various other types of therapies include the use of gene therapy [ 187 ], mRNA [ 188 ], siRNA [ 189 ], miRNA [ 190 ], and antisense oligonucleotides [ 191 ].…”

Section: Advanced Drug Delivery Systems In Epigeneticsmentioning

confidence: 99%

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Greeny,

Nair,

Sadanandan

et al. 2024

Biology

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative condition that predominantly affects the hippocampus and the entorhinal complex, leading to memory lapse and cognitive impairment. This can have a negative impact on an individual’s behavior, speech, and ability to navigate their surroundings. AD is one of the principal causes of dementia. One of the most accepted theories in AD, the amyloid β (Aβ) hypothesis, assumes that the buildup of the peptide Aβ is the root cause of AD. Impaired insulin signaling in the periphery and central nervous system has been considered to have an effect on the pathophysiology of AD. Further, researchers have shifted their focus to epigenetic mechanisms that are responsible for dysregulating major biochemical pathways and intracellular signaling processes responsible for directly or indirectly causing AD. The prime epigenetic mechanisms encompass DNA methylation, histone modifications, and non-coding RNA, and are majorly responsible for impairing insulin signaling both centrally and peripherally, thus leading to AD. In this review, we provide insights into the major epigenetic mechanisms involved in causing AD, such as DNA methylation and histone deacetylation. We decipher how the mechanisms alter peripheral insulin signaling and brain insulin signaling, leading to AD pathophysiology. In addition, this review also discusses the need for newer drug delivery systems for the targeted delivery of epigenetic drugs and explores targeted drug delivery systems such as nanoparticles, vesicular systems, networks, and other nano formulations in AD. Further, this review also sheds light on the future approaches used for epigenetic drug delivery.

show abstract

Section: Advanced Drug Delivery Systems In Epigeneticsmentioning

confidence: 99%

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Greeny,

Nair,

Sadanandan

et al. 2024

Biology

View full text Add to dashboard Cite

show abstract

“… 104 Recent advances in nano carrier-based gene therapy have enabled scientific organizations the capability and motivation to assess a wide range of prospective therapeutic options ( Figure 3 ). 107 In this context, nanomaterials as gene carriers have significantly increased the efficacy of gene therapy and minimized the enzymatic degradation of genetic components. 108 They initially researched in vivo gene delivery to brain disorders using organically modified silica NPs (ORMOSIL) ( Table 2 ).…”

Section: How Do Nanotechnology-based Therapeutic Approaches Target Br...mentioning

confidence: 99%

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

Mohapatra,

Gopikrishnan,

Doss C

et al. 2024

IJN

View full text Add to dashboard Cite

New nanotechnology strategies for enhancing drug delivery in brain disorders have recently received increasing attention from drug designers. The treatment of neurological conditions, including brain tumors, stroke, Parkinson’s Disease (PD), and Alzheimer’s disease (AD), may be greatly influenced by nanotechnology. Numerous studies on neurodegeneration have demonstrated the effective application of nanomaterials in the treatment of brain illnesses. Nanocarriers (NCs) have made it easier to deliver drugs precisely to where they are needed. Thus, the most effective use of nanomaterials is in the treatment of various brain diseases, as this amplifies the overall impact of medication and emphasizes the significance of nanotherapeutics through gene therapy, enzyme replacement therapy, and blood-barrier mechanisms. Recent advances in nanotechnology have led to the development of multifunctional nanotherapeutic agents, a promising treatment for brain disorders. This novel method reduces the side effects and improves treatment outcomes. This review critically assesses efficient nano-based systems in light of obstacles and outstanding achievements. Nanocarriers that transfer medications across the blood-brain barrier and nano-assisted therapies, including nano-immunotherapy, nano-gene therapy, nano enzyme replacement therapy, scaffolds, and 3D to 6D printing, have been widely explored for the treatment of brain disorders. This study aimed to evaluate existing literature regarding the use of nanotechnology in the development of drug delivery systems that can penetrate the blood-brain barrier (BBB) and deliver therapeutic agents to treat various brain disorders.

show abstract

“…Similarly, gene suppression aiming to reduce the expression of genes associated with AD is also being examined [ 95 ]. Small interfering RNA (siRNA) can also be used as a potential strategy in treating AD by targeting genes involved in the production of A β , a protein associated with the disease [ 96 ]. Challenges in delivering the gene to target cells in the brain and the immunogenicity associated with gene therapy remain concerns.…”

Section: Repurposed Drugs For Ad Therapymentioning

confidence: 99%

Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review

Beshir,

Hussain,

Menon

et al. 2024

International Journal of Alzheimer's Disease

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder caused by the accumulation of amyloid‐beta (Aβ) proteins and neurofibrillary tangles in the brain. There have been recent advancements in antiamyloid therapy for AD. This narrative review explores the recent advancements and challenges in antiamyloid therapy. In addition, a summary of evidence from antiamyloid therapy trials is presented with a focus on lecanemab. Lecanemab is the most recently approved monoclonal antibody that targets Aβ protofibrils for the treatment of patients with early AD and mild cognitive impairment (MCI). Lecanemab was the first drug shown to slow cognitive decline in patients with MCI or early onset AD dementia when administered as an infusion once every two weeks. In the Clarity AD trial, lecanemab was associated with infusion‐site reactions (26.4%) and amyloid‐related imaging abnormalities (12.6%). The clinical relevance and long‐term side effects of lecanemab require further longitudinal observation. However, several challenges must be addressed before the drug can be routinely used in clinical practice. The drug’s route of administration, need for imaging and genetic testing, affordability, accessibility, infrastructure, and potential for serious side effects are some of these challenges. Lecanemab’s approval has fueled interest in the potential of other antiamyloid therapies, such as donanemab. Future research must focus on developing strategies to prevent AD; identify easy‐to‐use validated plasma‐based assays; and discover newer user‐friendly, and cost‐effective drugs that target multiple pathways in AD pathology.

show abstract

Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer’s disease

Cited by 11 publications

References 100 publications

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review

Contact Info

Product

Resources

About